Oxeia Biopharmaceuticals, Inc.

Japan has cautiously granted a conditional, global-first approval to SanBio Co., Ltd ’s autologous mesenchymal stem cell (MSC)-based therapy Akuugo (vandefitemcel; SB623) for traumatic brain injury (

The NOSTRA III study of Germany’s Vasopharm GmbH ’s inducible nitric oxide synthase inhibitor ronopterin (VAS203) has missed its primary endpoint in patients with traumatic brain injury (TBI), but th